cover
Article Per Year (5 Year)
All
Home Page
OAI Link
Editorial Team
Contact
Reviewer
Google Scholar
Contact Name
Bayu Brahma
Contact Email
journal.cancer@gmail.com
Phone
+628176389956
Journal Mail Official
admin@indonesianjournalofcancer.or.id
Editorial Address
National Cancer Center - Dharmais Cancer Hospital Research and Development Building, 3rd-floor Jl. Letjen S. Parman Kav. 84-86, Slipi West Jakarta
Location
Kota adm. jakarta barat,
Dki jakarta
INDONESIA
Indonesian Journal of Cancer
Published by National Cancer Center-Dharmais Cancer Hospital
ISSN : 19783744     EISSN : 23556811     DOI : https://www.doi.org/ 10.33371
Core Subject : Health, Science,
Biochemistry, Genetics & Molecular Biology Immunology & microbiology Medicine & Pharmacology Public Health
Indonesian Journal of Cancer is a peer-reviewed and open-access journal. This journal is published quarterly (in March, June, September, and December) by Dharmais Cancer Hospital - National Cancer Center. Submissions are reviewed under a broad scope of topics relevant to experimental and clinical cancer research. Articles are original research that needs to be disseminated and written in English. All submitted manuscripts will go through the double-blind peer review and editorial review before being granted acceptance for publication. The journal publishes original research articles, case reports, and review articles under the following categories: cancer management, cancer prevention, cancer etiology, epidemiology, molecular oncology, cancer diagnosis and therapy, tumor pathology, surgical oncology, medical oncology, radiation oncology, interventional radiology, as well as early detection.
Arjuna Subject : Kedokteran - Onkologi
Articles 562 Documents
 51   52   53   54   55 
Clinical Response Description of Primary Brain Tumor Patients with Radiotherapy at The Radiation Oncology Department, Dr. Hasan Sadikin General Hospital, Bandung Lestari, Windha; Utama, Marhendra Satria; Baraqbah, Hasan
Indonesian Journal of Cancer Vol 19, No 3 (2025): September
Publisher : http://dharmais.co.id/

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33371/ijoc.v19i3.1265

Abstract

Background: Brain tumors, marked by abnormal cell divisions, are classified as primary or secondary based on their origin. Effective management involves a comprehensive strategy, with radiotherapy employed as definitive, adjuvant, or palliative treatment. This study aimed to examine the clinical responses of primary brain tumor patients receiving radiotherapy at RSUP Dr. Hasan Sadikin, Bandung, from 2020 to 2022.Method: This descriptive research utilized total sampling, including 19 medical records of primary brain tumor patients who underwent radiotherapy at Hasan Sadikin Bandung Central General Hospital between 2020 and 2022.Results: Primary brain tumor patients undergoing radiotherapy were primarily aged 0-18 years (47.4%), predominantly female (63.2%), and from the West Priangan region (36.8%), with headaches as the chief complaint (47.4%). Tumor grading was evenly distributed among grades 1, 3, and 4 (26.7% each), with the main anatomical locations in the temporal lobe and cerebellum (33.3% each). Histopathologically, astrocytoma and medulloblastoma were most common (21% each), and the majority received adjuvant radiation therapy (57.9%), primarily via Intensity Modulated Radiation Therapy (IMRT) (68.4%). All patients received doses ≤ 2 Gy per fraction (100%), with most receiving 20 fractions (94.7%). The mean time to start radiotherapy was 44.37 ± 22.25 days, and the mean duration was 88.11 ± 21.32 days post-diagnosis. Tumor size decreased from 4.33±1.66 cm before treatment to 1.28±1.74 cm afterward, with 50% of patients achieving a complete clinical response.Conclusion: Children and adolescents (0-18 years) from West Priangan, primarily females, made up the majority of primary brain tumor patients receiving radiotherapy. Headache was the most common symptom, with tumors mostly in the temporal lobe and cerebellum. Astrocytoma and medulloblastoma were the dominant histopathological types. Patients primarily underwent IMRT, with doses ≤ 2 Gy per fraction, often over more than 20 fractions. Radiotherapy lasted between 44 and 88 days, significantly reducing tumor size, and most patients had a complete response.
Giant Malignant Phyllodes Tumor in a 36-year-old Female: A Rare Case Report Betty, Betty; Hasibuan, Arie Widiansyah; Siregar, Denny Rifsal
Indonesian Journal of Cancer Vol 19, No 3 (2025): September
Publisher : http://dharmais.co.id/

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33371/ijoc.v19i3.1315

Abstract

Introduction: Phyllodes tumor (PT) is infrequent among breast neoplasms, representing less than 1% of all breast neoplasms, with 10% to 30% of them being malignant. The occurrence rate of malignant phyllodes tumor (MPT) is about 2.1 cases per million people.Case Presentation: We report the case of a 36-year-old female who had a significant mass in her right breast. Macroscopically, the cut surface was grayish-white with cystic areas containing a hemorrhagic mass; the tumor occupied nearly the entire breast with indistinct borders. The tumor measured 26 x 16 x 11 cm. Microscopically, the tumor exhibited a solid structure with ductal proliferation and hypercellular stroma forming a leaf-like appearance. Proliferation of fibrous connective tissue with dysplastic cell morphology and atypical mitoses was found in 10/10 high-power fields (HPFs). Malignant heterologous components included bone matrix with osteoclast-like giant cells and chondroid components. Immunohistochemical Ki-67 staining was positive in more than 20% of the cell nuclei.Conclusion: The tumor is large with unclear infiltration boundaries and contains malignant heterologous components. Immunohistochemical Ki-67 staining was positive in more than 20% of the cell nuclei, confirming this as a case of malignant phyllodes tumor. This case is notable due to its rarity, frequent recurrence, and the challenges in establishing a diagnosis and treatment regimen.
Comparative Review of the Potential of 177Lu-PSMA-617 and Docetaxel Chemotherapy in the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC) Rahmawati, N. Anna Sakinah Liana; Hutapea, Ezra Calista; Holik, Holis Abdul
Indonesian Journal of Cancer Vol 19, No 3 (2025): September
Publisher : http://dharmais.co.id/

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33371/ijoc.v19i3.1296

Abstract

Background: Prostate cancer has witnessed a substantial rise in both prevalence and risk over the years. In 2022, it is expected to rank fourth in terms of annual cancer-related mortality.  The treatment of prostate cancer involves the administration of chemotherapy using conventional drugs such as docetaxel. The most recent advancement in treating metastatic castration-resistant prostate cancer (mCRPC) is 177Lu-PSMA-617, a radioligand therapy. This treatment combines radioactive and ligand elements, resulting in exceptionally effective outcomes. This review aims to compare the potential of 177Lu-PSMA and Docetaxel in terms of production, side effects, prostate-specific antigen (PSA) reduction, and associated costs.Methods:  This literature review examines the differences in the therapeutic effectiveness of 177Lu-PSMA-617 and docetaxel monotherapy or in combination in patients with mCRPC.  Relevant research on both treatment options was searched, focusing on human clinical trials and case reports published between 2010 and 2024. Article selection was conducted in databases such as PubMed, Scopus, Springer, Elsevier, and NCBI.Results: Based on the eight articles included in this review, 177Lu-PSMA-617 can be regarded as an alternative therapy for patients with mCRPC. 177Lu-PSMA-617 and docetaxel can both decrease PSA levels by ≥50%. However, it's important to note that 177Lu-PSMA-617 is more expensive than docetaxel. Furthermore, the adverse effects of 177Lu-PSMA-617 are relatively less severe compared to those of docetaxel.Conclusions: The comparative results between docetaxel and 177Lu PSMA demonstrate that both therapies exhibit similar efficacy in reducing PSA levels. The results indicate that radioligand therapy 177Lu-PSMA-617 can be used as an alternative treatment for mCRPC with the potential for cure and minimal side effects. The cost can be minimized by increasing the utilization of radioligand 177Lu-PSMA-617, as higher usage leads to decreased prices.
Incidental Histopathologic Findings of Uterine Leimyosarcoma in a 58-year-old Woman: A Rare Case Report Paskarani, Putu Erika; Hutapea, N. Yuliance Nurhawati; Widiyanti, Endang Sri; Nini, Cheryl; Sinaga, Naomi Juliana
Indonesian Journal of Cancer Vol 19, No 3 (2025): September
Publisher : http://dharmais.co.id/

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33371/ijoc.v19i3.1335

Abstract

Introduction: Leiomyosarcoma accounts for (~40–50%) of all uterine sarcomas, but only 1-2% of all uterine malignancies. The incidence of leiomyosarcoma increases with age, reaching its peak in the seventh decade of life. Here, we proposed the importance of macroscopic and microscopic criteria of leiomyosarcoma to ensure clinical diagnosis.Case Presentation: A 58-year-old woman came with vaginal bleeding for 3 weeks before admission to the hospital.  The ultrasonography (USG) examination showed enlargement of the uterus and was clinically diagnosed as a leiomyoma. However, on histopathological examination, a proliferation of anaplastic cells was revealed, forming fasciculi that intersect each other and infiltrate into the connective tissue stroma. Mitosis 15/50 HPF and abnormal mitosis with abrupt coagulative necrosis are easily found. The histopathologic examination concluded that the patient had uterine leiomyosarcoma (pT1a), FIGO stage 1B.Conclusion: Histopathological examination and a clinicoradiological approach are key to identifying leiomyosarcoma. In most cases, although it is confined to the uterus, it has a poor prognosis. Otherwise, this case has a more favorable outcome due to the pathological and clinical stage, with 5-year survival rates of 40 – 70%
Primary Bone Diffuse Large B-Cell Lymphoma: A Case Series and Review of Literature Ramkita, Nora; Murti, Krisna; Devi, SNA Ratna Sari; Dwiryanti, Rizky
Indonesian Journal of Cancer Vol 19, No 3 (2025): September
Publisher : http://dharmais.co.id/

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33371/ijoc.v19i3.1272

Abstract

Introduction: Primary bone lymphoma (PBL) is an uncommon lymphoid cell neoplasm that appears as one or more bone lesions and does not appear in any lymph nodes or other places outside the lymph nodes. This type accounts for approximately 1% of all lymphomas and 7% of all cancerous primary bone tumors.Case Presentation: We collected two respective cases of primary bone lymphoma in the Department of Anatomic Pathology, Faculty of Medicine, Sriwijaya University, Dr. Mohammad Hoesin General Hospital, Palembang, Indonesia. Both cases were diffuse large B-cell lymphoma, non-germinal center subtype (DLBCL non-GCB), in individuals 48 and 18 years old, located in the right femur. The prognosis for both patients was poor due to the advanced stage, as well as the second patient's refusal of chemotherapy. Conclusion: These cases demonstrate the diagnostic and therapeutic challenges of primary bone diffuse large B-cell lymphoma, particularly the aggressive non-GCB subtype. Early recognition, accurate histopathological diagnosis, and prompt, multidisciplinary management are essential to improve prognosis, especially in advanced-stage presentations. Delay in treatment or refusal of therapy significantly worsens patient outcomes.
Mutation of BRCA1/2 Gene in Premenopausal Triple-Negative Breast Cancer Patients in West Sumatera Harahap, Wirsma Arif; Khambri, Daan; Panigoro, Sonar Soni; Hafiz, Muhammad Zaki Abdul
Indonesian Journal of Cancer Vol 19, No 1 (2025): March
Publisher : http://dharmais.co.id/

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33371/ijoc.v19i1.1255

Abstract

Background: The BRCA1/2 mutation rate was found to be higher in triple-negative breast cancer (TNBC) patients depending on young age, and the presence of a family history of breast cancer and ovarian cancer. Research on BRCA1/2 germline mutations that focused on premenopausal TNBC patients in Indonesia has never been carried out. The objective of this research is to determine the BRCA1/2 germline gene mutation status in premenopausal TNBC patients in West Sumatra.Methods: This is a descriptive study conducted at the Surgical Oncology Division of DR. M. Djamil Hospital, Padang from April to July 2023. This study included patients aged 50 years who were diagnosed with the TNBC subtype at Dr. M. Djamil Hospital, Padang from January 2016 to July 2023. Secondary data was collected through the patient’s medical records to observe the TNBC patient’s characteristics. A blood test of TNBC patients was carried out to determine germline mutation of BRCA1/2.Results: 22 patients with TNBC participated in the study. In this study, 4/22 (18.2%) had BRCA2 pathogenic mutations and no BRCA1 pathogenic mutation was found. All patients with BRCA2 pathogenic mutation have the same mutation characteristics, i.e exon 3, genetic variation (c.262_263delCT), amino acids (p.Leu88AlafsTer12), and type of mutation (Frameshift Deletion). Conclusions: TNBC patients in West Sumatra have BRCA2 pathogenic mutations with the same characteristics as the mutations
The Impact of Antitumor Treatment on Cancer Patients with COVID-19: A Systematic Review and Meta-Analysis Ananto, Farizky Jati; Purwanto, Heru; Ayuda, Caesar; Wibiseno, Dono Marsetio; Putra, Probo Yudha Pratama; Wardhana, Burhan Mahendra Kusuma; Putra, Doddy Setya Adi
Indonesian Journal of Cancer Vol 18, No 3 (2024): September
Publisher : http://dharmais.co.id/

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33371/ijoc.v18i3.1158

Abstract

Background: Cancer is a chronic disease that can cause various complications, decrease the immune system, reduce quality of life, and even lead to death. In addition, the COVID-19 pandemic in various countries has had a significant adverse impact on patients. This study analyzed the impact of various antitumor treatments on cancer patients with COVID-19. Methods: This meta-analysis was conducted according to the PRISMA – P pathway. Source searches were conducted in PubMed, Cochrane Library, Research Gate, and Science Direct in cancer patients with COVID-19 receiving various types of antitumor treatment. Analysis was performed using RevMan V.5.3 software with the outcome of mortality rate and severe COVID-19. Results: Twenty-five observational studies met the inclusion criteria with a total of 21,940 patients. There was no significant difference in mortality rate (OR 1.08, 95% CI 0.99 – 1.18, p = 0.09), but there was a significant difference in severe COVID-19 (OR 1.19, 95% CI 1.02 – 1.39, p = 0.02). Immunotherapy provided the most significant worsening of both mortality rate (OR 1.39, 95% CI 1.17 – 1.64, p = 0.0001) and severe COVID-19 (OR 1.82, 95% CI 1.23 – 2.71, p = 0.003). There were no significant differences in other antitumor treatments. Conclusions: Antitumor treatment does not have a significant impact on mortality rate, but has a significant impact on worsening the degree of COVID-19. Among all the antitumor therapies that provide the highest potential for worsening is immunotherapy.
Myxofibrosarcoma of The Abdominal Wall at Moewardi Hospital, Surakarta: A Rare Case Report Soewoto, Widyanti; Ismail, Erwin Aritama; Bellynda, Monica
Indonesian Journal of Cancer Vol 18, No 2 (2024): June
Publisher : http://dharmais.co.id/

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33371/ijoc.v18i2.1018

Abstract

Introduction: Myxofibrosarcoma (MFS) is a fibroblast-derived sarcoma, which accounts for approximately 5–10% of all soft tissue malignant tumors. The mean age in patients with MFS is between the fifth and seventh decades. Around 77% of MFS cases occur in the upper extremities. Other areas of the body including the trunk (12%), retroperitoneum or mediastinum (8%), abdominal wall, and heart have also been reported. Case Presentation: A 57-year-old Indonesian female visited our center with complaints of a lump in the left lower abdomen for 4 months. The lump has grown rapidly in the last two months. A contrast abdominal MRI examination found a soft tissue mass on the left lumbar abdominal wall to the left iliac with a size of 15 x 11,4 x 13,4 cm and bordered by part of the left external oblique muscle and the left internal oblique muscle pushing the intestinal system medially. The biopsy of the mass revealed a high-grade myxofibrosarcoma. The patient underwent a wide excision with an elliptical incision design, with in-toto removal of the lump. The immunohistochemical result of the tumor showed high-grade myxofibrosarcoma with free margins at the incision margin. Follow-up was performed at 1 month, 6 months, and 12 months postoperatively. The patient did not receive radiotherapy. Conclusions: This report describes a rare case of MFS of the abdominal wall. Recognizing the histopathological features of MFS and applying the appropriate immunohistochemical examinations are crucial in establishing the correct diagnosis. This case provides a diagnosis and treatment experience of MFS that occurs in the abdominal wall.
Clinical Symptoms of Patients with Early-Stage and Advanced-Stage Ovarian Cancer Shofwana, Haura Almash Aulia; Hidayati, Hanik Badriyah; Saraswati, Wita; Tjokroprawiro, Brahmana Askandar
Indonesian Journal of Cancer Vol 18, No 3 (2024): September
Publisher : http://dharmais.co.id/

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33371/ijoc.v18i3.1134

Abstract

Background: Ovarian cancer is a malignant neoplasm originating from ovarian cells with different histological types depending on the subtype. It can affect women of all ages. Ovarian cancer ranks third in terms of incidence among diagnosed female cancer patients, following breast and cervical cancer. Ovarian cancer often doesn’t present specific/clear symptoms. As a result, only a small number of patients are diagnosed at an early stage (20%). The study aimed to analyze the clinical complaints experienced by ovarian cancer patients, both in early and advanced stages before diagnosis. Methods: This descriptive cross-sectional study analyzes clinical complaints before the diagnosis of early and advanced-stage ovarian cancer patients. The study was conducted in the Gynecology-Oncology inpatient ward at Dr. Soetomo Regional General Hospital in 2021, utilizing medical record data. Results: A total of 98 patients (21 patients with early-stage, and 77 patients with advanced-stage) were analyzed. The majority of the patients are aged 45-58 years (49%), work as homemakers (32.7%), and are married (63.3%). The three most common complaints experienced by subjects with early-stage ovarian cancer were abdominal/pelvic pain (23.8%), abdominal/pelvic pressure (28.6%), and abdominal distension (42.9%), while in patients with advanced-stage ovarian cancer were abdominal/ pelvic pain (32.7%), abdominal distension (42.9%), and abdominal discomfort (bloating, early satiety, feeling of fullness, frequent belching, heartburn, nausea and vomiting) (44.2%). Conclusions: The three most common clinical complaints among patients before being diagnosed with early and advanced-stage ovarian cancer in the inpatient ward of Dr. Soetomo Regional General Hospital Surabaya in 2021 were similar. The recognition of these complaints and several risk factors are expected to assist in the earlier diagnosis of ovarian cancer.
Acute Myeloid Leukemia in a Three-Year-Old Girl Mimicking Chronic Myeloid Leukemia in Blast Crisis, Challenge in Diagnosis and Treatment in Limited-Resourced Health Care Facility: A Case Report Predani, Ni Luh Putu Diaswari; Gunawan, Andre; Mustika, Putu Pradnyanita; Tedja, I Gusti Ayu Wiradari
Indonesian Journal of Cancer Vol 18, No 1 (2024): March
Publisher : http://dharmais.co.id/

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33371/ijoc.v18i1.1073

Abstract

Introduction: : Acute myeloid leukemia (AML) is the second most common hematologic cancer in childhood. Clinically, AML has similar symptoms to other types of leukemias, and diagnosis remains a challenge due to limited access to pediatric hemato-oncology diagnostic examination. This study aims to report AML in a 3-year-old girl who was first suspected of Chronic Myeloid Leukemia (CML) in blast crisis, using a combination of clinical-hematology parameters and conventional morphology examination in a limited-resourced healthcare facility. Case Presentation: A 3-year-old girl was referred from a rural Eastern Indonesia hospital with symptoms of prolonged fever, leucocytosis, severe anemia, and severe thrombocytopenia. In the previous hospital, the patient had a history of hyperleukocytosis and peripheral blood smear suspected of CML in blast crisis. A peripheral blood smear was repeated in our hospital and showed findings of Auer rod cells suggesting AML. Two bags of packed red cells and 2 thrombocyte concentrations were administered before referral for further diagnostic evaluation with bone marrow aspiration. Bone marrow aspiration revealed multiple nucleoli suggested for AML with FAB classification as M4 subtypes, and she received chemotherapy in a tertiary hospitalConclusions: With limited resources, suspicion based on persistent clinical symptoms, routine hematology tests, and peripheral blood smear examination are important to distinguish AML from CML in blast crisis. Understanding clinical hematology parameters and peripheral blood smears is the first step in AML diagnosis pathway and decision for further diagnostic referral. Supportive therapy and early recognition of oncologic emergency must be done before referral to a tertiary referral hospital.

Page 53 of 57 | Total Record : 562

 51   52   53   54   55 

Filter by Year

2007 2025


Reset
Filter By Issues
All Issue Vol 19, No 3 (2025): September Vol 19, No 2 (2025): June Vol 19, No 1 (2025): March Vol 18, No 4 (2024): December Vol 18, No 3 (2024): September Vol 18, No 2 (2024): June Vol 18, No 1 (2024): March Vol 17, No 4 (2023): December Vol 17, No 3 (2023): September Vol 17, No 2 (2023): June Vol 17, No 1 (2023): March Vol 16, No 4 (2022): December Vol 16, No 3 (2022): September Vol 16, No 2 (2022): June Vol 16, No 1 (2022): March Vol 15, No 4 (2021): December Vol 15, No 3 (2021): September Vol 15, No 2 (2021): June Vol 15, No 1 (2021): March Vol 14, No 4 (2020): December Vol 14, No 3 (2020): September Vol 14, No 2 (2020): June Vol 14, No 1 (2020): March Vol 13, No 4 (2019): December Vol 13, No 3 (2019): September Vol 13, No 2 (2019): June Vol 13, No 1 (2019): March Vol 12, No 4 (2018): October-December Vol 12, No 3 (2018): July-September Vol 12, No 2 (2018): April-June Vol 12, No 1 (2018): Jan - Mar Vol 11, No 4 (2017): October- December 2017 Vol 11, No 3 (2017): July - September 2017 Vol 11, No 2 (2017): April - June Vol 11, No 1 (2017): Jan-Mar Vol 10, No 4 (2016): October - December 2016 Vol 10, No 3 (2016): July - September 2016 Vol 10, No 2 (2016): April - June 2016 Vol 10, No 1 (2016): Jan - Mar 2016 Vol 9, No 4 (2015): Okt - Des 2015 Vol 9, No 3 (2015): Jul - Sept 2015 Vol 9, No 2 (2015): April-Juni 2015 Vol 9, No 1 (2015): Jan - Mar 2015 Vol 8, No 4 (2014): Oct - Dec 2014 Vol 8, No 3 (2014): Jul - Sep 2014 Vol 8, No 2 (2014): April-Juni 2014 Vol 8, No 1 (2014): Jan - Mar 2014 Vol 7, No 4 (2013): Oct - Dec 2013 Vol 7, No 3 (2013): Jul - Sep 2013 Vol 7, No 2 (2013): Apr - Jun 2013 Vol 7, No 1 (2013): Jan - Mar 2013 Vol 6, No 4 (2012): Oct - Dec 2012 Vol 6, No 3 (2012): Jul - Sep 2012 Vol 6, No 2 (2012): Apr - Jun 2012 Vol 6, No 1 (2012): Jan - Mar 2012 Vol 5, No 4 (2011): Oct - Dec 2011 Vol 5, No 3 (2011): Jul - Sep 2011 Vol 5, No 2 (2011): Apr - Jun 2011 Vol 5, No 1 (2011): Jan - Mar 2011 Vol 4, No 4 (2010): Oct - Dec 2010 Vol 4, No 3 (2010): Jul - Sep 2010 Vol 4, No 2 (2010): Apr - Jun 2010 Vol 4, No 1 (2010): Jan - Mar 2010 Vol 3, No 4 (2009): Oct - Dec 2009 Vol 3, No 3 (2009): Jul - Sep 2009 Vol 3, No 2 (2009): Apr - Jun 2009 Vol 3, No 1 (2009): Jan - Mar 2009 Vol 2, No 4 (2008): Oct - Dec 2008 Vol 2, No 3 (2008): Jul - Sep 2008 Vol 2, No 2 (2008): Apr - Jun 2008 Vol 2, No 1 (2008): Jan - Mar 2008 Vol 1, No 4 (2007): Oct - Dec 2007 Vol 1, No 3 (2007): Jul - Sep 2007 Vol 1, No 2 (2007): Apr - Jun 2007 Vol 1, No 1 (2007): Jan - Mar 2007 More Issue